Is NCT05361720 recruiting in Nashville, TN?

Yes, NCT05361720 is currently recruiting participants at its Nashville, TN location. This kidney cancer clinical trial is actively enrolling qualified participants.

How do I join the kidney cancer clinical trial in Nashville?

To join this clinical trial in Nashville, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Nashville clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Kidney Cancer Clinical Trial in Nashville, TN

About This Kidney Cancer Study in Nashville

This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenou

Sponsor: Vanderbilt-Ingram Cancer Center

Who Can Participate

Inclusion Criteria

Histological confirmation of RCC with a clear cell component

Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American Joint Committee on Cancer \[AJCC\] stage IV) RCC

Patient can comprehend and sign the study informed consent form

Male or female \>= 18 years of age at the time of informed consent

Karnofsky performance status (KPS) of \>= 70%

No prior systemic therapy for RCC in the neoadjuvant, adjuvant or metastatic setting

At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Tumor tissue for ribonucleic acid (RNA)-sequencing (tumor tissue from bony metastasis is not suitable but a soft tissue component around bone is acceptable)

Screening tissue consent- Patient must be assigned to either Cluster 1/2 or 4/5. Patients assigned to cluster 3/6/7 will not be eligible for the treatment study

Adequate renal function defined as calculated creatinine clearance \>= 30 mL/min per the Cockcroft and Gault formula

Adequate liver function defined by:

Total bilirubin =\< 1.5 times the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during screening and prior to receiving first dose of protocol-indicated treatment

Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal

Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 years of age in the absence of other biological or physiological causes

Exclusion Criteria

=\< 14 days before first dose of protocol-indicated treatment:

Major surgery requiring general anesthesia

Inadequately controlled hypertension (systolic blood pressure \[SBP\] \> 160/90 mmHg)

Anti-hypertensive medications are permitted.

Active infection requiring infusional treatment

Has preexisting gastrointestinal or non-gastrointestinal fistula

Proteinuria \> 2 g/ 24 hours (hrs)

If patient has 1+ protein on urine dipstick then a 24 hr urine collection is required

Non-healing wounds on any part of the body (for patients assigned to Cabo/Nivo only)

Known clinically significant active bleeding including hemoptysis

Inability to swallow oral medication; or the presence of a poorly controlled gastrointestinal disorder that could significantly affect the absorption of oral study drug (for patients assigned to Cabo/Nivo only) - e.g., Crohn's disease, ulcerative colitis, chronic diarrhea (defined as \> 4 loose stools per day), malabsorption, or bowel obstruction

Significant cardiovascular disease or condition including:

Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) functional criteria

Unstable angina pectoris (i.e., last episode =\< 3 months prior to first dose of protocol-indicated treatment)

Myocardial infarction within 3 months prior to starting treatment

Subjects with central nervous system (CNS) metastases are eligible after they have completed local therapy (e.g., whole brain radiation therapy \[WBRT\], surgery or radiosurgery)

Any condition requiring systemic treatment with either systemic corticosteroids (\> 10 mg/day prednisone or equivalent daily) or other immunosuppressive medications within 14 days prior to initiating protocol-indicated treatment

In the absence of active autoimmune disease: Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g., topical, ocular, intra-articular, intranasal, and inhalational), =\< 10 mg/day prednisone or equivalent daily; and physiologic replacement doses of systemic corticosteroids =\< 10 mg/day prednisone or equivalent daily (e.g., hormone replacement therapy needed in patients with hypophysitis)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT05361720) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Kidney Cancer Treatment Options in Nashville, TN

If you're searching for kidney cancer treatment options in Nashville, TN, this clinical trial (NCT05361720) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced kidney cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all kidney cancer clinical trials near you to find additional studies recruiting in your area.

Kidney Cancer Clinical Trial in Nashville, TN

Expert Care in Nashville

IRB Approved

No-Cost Care

Apply for This Nashville Location

Why Participate?

Simple Process